Bretylium p-toluenesulfonate
Bretylium p-toluenesulfonate Brand names, Bretylium p-toluenesulfonate Analogs
Bretylium p-toluenesulfonate Brand Names Mixture
- No information avaliable
Bretylium p-toluenesulfonate Chemical_Formula
C11H17BrN+
Bretylium p-toluenesulfonate RX_link
http://www.rxlist.com/cgi/generic3/bretosy.htm
Bretylium p-toluenesulfonate fda sheet
Bretylium p-toluenesulfonate msds (material safety sheet)
Bretylium p-toluenesulfonate Synthesis Reference
No information avaliable
Bretylium p-toluenesulfonate Molecular Weight
243.163 g/mol
Bretylium p-toluenesulfonate Melting Point
No information avaliable
Bretylium p-toluenesulfonate H2O Solubility
Freely soluble
Bretylium p-toluenesulfonate State
Solid
Bretylium p-toluenesulfonate LogP
No information avaliable
Bretylium p-toluenesulfonate Dosage Forms
Solution for injection (50mg/mL)
Bretylium p-toluenesulfonate Indication
For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.
Bretylium p-toluenesulfonate Pharmacology
Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.
Bretylium p-toluenesulfonate Absorption
No information avaliable
Bretylium p-toluenesulfonate side effects and Toxicity
Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.
Bretylium p-toluenesulfonate Patient Information
Bretylium p-toluenesulfonate Organisms Affected
Humans and other mammals
